Banner

Pegfilgrastim Biosimilars Global Market Report 2023 – By Application (Chemotherapy Treatment, Transplantation, Other Applications), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Mail-Order Pharmacies) – Market Size, Trends, And Market Forecast 2023-2032

Starting Price : $5000.00 | Pages : 250 | Published : January 2023 | SKU CODE : h1162 | Delivery Time: 2-3 business days | Format :


Pegfilgrastim biosimilars refer to a biosimilar that is intended to be used in conjunction with supportive care for people with non-myeloid cancer. It can help prevent or treat infections brought on by myelosuppressive chemotherapy by promoting the formation of certain white blood cells.

The different applications of pegfilgrastim biosimilars are chemotherapy treatment, transplantation, and others. Chemotherapy is a cancer treatment that involves the administration of one or more anti-cancer medications as part of a defined protocol. The various distribution channels include hospital pharmacies, retail pharmacies, and mail-order pharmacies.

The pegfilgrastim biosimilars market research report is one of a series of new reports from The Business Research Company that provides pegfilgrastim biosimilars market statistics, including pegfilgrastim biosimilars industry global market size, regional shares, competitors with a pegfilgrastim biosimilars market share, detailed pegfilgrastim biosimilars market segments, market trends and opportunities, and any further data you may need to thrive in the pegfilgrastim biosimilars industry. This pegfilgrastim biosimilars market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The global pegfilgrastim biosimilars market grew from $1.28 billion in 2022 to $1.41 billion in 2023 at a compound annual growth rate (CAGR) of 10.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The pegfilgrastim biosimilars market is expected to grow from $2.04 billion in 2027 at a CAGR of 9.7%.

Government initiatives for the development of biosimilars are expected to drive the pegfilgrastim biosimilars market. Governments worldwide are focusing on the development of biosimilars due to their cost-effective nature. The US Food and Drug Administration (FDA) launched a Biosimilar Action Plan, to increase treatment options. The Australian government is committed to the Biosimilar Awareness Initiative, and they improved their commitment by supporting the Generic and Biosimilar Medicines Association through a grant of $5 million to accept increased general biosimilar education and activities that promote the suitable dispensing, prescription, and use of biosimilar medicines. Hence, the government initiatives for the development of biosimilars aid in the increased production and awareness that, in turn, support the growth of the pegfilgrastim biosimilars market.

The FDA's low number of drug approvals hampered the pegfilgrastim biosimilar market during the forecast period.The market currently has only four drugs approved for treatment, thus restricting the growth of the market. This can be attributed to strict standards for manufacturing and high drug efficacy standards set by the regulatory bodies for approval of this therapy, thus increasing the time required for approval and limiting the growth of the market.

Companies in the pegfilgrastim biosimilar market are increasing their product innovation through strategic collaborations. To sustain themselves in the increasingly competitive market, companies are developing innovative products as well as sharing skills and expertise with other companies. While companies have long collaborated with academic and research institutions in this market by way of partnerships or out-licensing deals, this trend has been increasing over the past few years. For instance, in April 2020, Biocon, an India-based biopharmaceutical company, partnered with Mylan, a US-based generic and specialty pharmaceuticals company, to introduce Fulphila, a biosimilar pegfilgrastim, in Australia. Fulphila has been licenced by the Therapeutic Goods Administration for the therapy of oncology patients who have had chemotherapy to shorten the length of acute neutropenia and hence the risk of infection, as evidenced by febrile neutropenia.

In February 2022, Biocon Biologics Ltd., an India-based fully integrated biopharmaceutical company, acquired Viatris ' biosimilar business for $3.34 billion. Through this acquisition, BBL would be able to direct-market more of its existing and upcoming biosimilars. In order to maintain customer service and facilitate a smooth transition to BBL, Viatris is expected to provide commercial and other transition services with this acquisition for an anticipated two-year term. Viatris Inc is a US-based pharmaceutical and healthcare corporation that has co-developed a biosimilar of pegfilgrastim.

Major players in the pegfilgrastim biosimilars market are Mylan, Biocon, Mundipharma, Pfizer, Sandoz, Coherus, Intas Pharmaceuticals, and Fresenius Kabi.

North America was the largest region in the pegfilgrastim biosimilars market in 2022. The Middle East is expected to be the fastest growing region in the global pegfilgrastim biosimilars market during the forecast period. The regions covered in the global pegfilgrastim biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

The countries covered in the pegfilgrastim biosimilars market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA.

The pegfilgrastim biosimilars market consists of sales of fulphila, pelgraz, pelmeg, udenyca, ziextenzo, grasustek, fylnetra, and stimufend. Values in this market are "factory gate values," that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products.

The global pegfilgrastim biosimilars market is segmented -

1) By Application: Chemotherapy Treatment, Transplantation, Other Applications

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Mail-Order Pharmacies

    Table Of Contents

    1. Executive Summary

    2. Pegfilgrastim Biosimilars Market Characteristics

    3. Pegfilgrastim Biosimilars Market Trends And Strategies

    4. Pegfilgrastim Biosimilars Market – Macro Economic Scenario

    4.1 COVID-19 Impact On Pegfilgrastim Biosimilars Market

    4.2 Ukraine-Russia War Impact On Pegfilgrastim Biosimilars Market

    4.3 Impact Of High Inflation On Pegfilgrastim Biosimilars Market

    5. Pegfilgrastim Biosimilars Market Size And Growth

    5.1. Global Pegfilgrastim Biosimilars Historic Market, 2017-2022, $ Billion

    5.1.1. Drivers Of The Market

    5.1.2. Restraints On The Market

    5.2. Global Pegfilgrastim Biosimilars Forecast Market, 2022-2027F, 2032F, $ Billion

    5.2.1. Drivers Of The Market

    5.2.2. Restraints On the Market

    6. Pegfilgrastim Biosimilars Market Segmentation

    6.1. Global Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    Chemotherapy Treatment

    Transplantation

    Other Applications

    6.2. Global Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    Hospital pharmacies

    Retail pharmacies

    Mail-Order pharmacies

    7. Pegfilgrastim Biosimilars Market Regional And Country Analysis

    7.1. Global Pegfilgrastim Biosimilars Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    7.2. Global Pegfilgrastim Biosimilars Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    8. Asia-Pacific Pegfilgrastim Biosimilars Market

    8.1. Asia-Pacific Pegfilgrastim Biosimilars Market Overview

    Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

    8.2. Asia-Pacific Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    9. China Pegfilgrastim Biosimilars Market

    9.1. China Pegfilgrastim Biosimilars Market Overview

    9.2. China Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion

    10. India Pegfilgrastim Biosimilars Market

    10.1. India Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    11. Japan Pegfilgrastim Biosimilars Market

    11.1. Japan Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    12. Australia Pegfilgrastim Biosimilars Market

    12.1. Australia Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    13. Indonesia Pegfilgrastim Biosimilars Market

    13.1. Indonesia Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    14. South Korea Pegfilgrastim Biosimilars Market

    14.1. South Korea Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    15. Western Europe Pegfilgrastim Biosimilars Market

    15.1. Western Europe Pegfilgrastim Biosimilars Market Overview

    15.2. Western Europe Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    16. UK Pegfilgrastim Biosimilars Market

    16.1. UK Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    17. Germany Pegfilgrastim Biosimilars Market

    17.1. Germany Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    18. France Pegfilgrastim Biosimilars Market

    18.3. France Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    19. Eastern Europe Pegfilgrastim Biosimilars Market

    19.1. Eastern Europe Pegfilgrastim Biosimilars Market Overview

    19.2. Eastern Europe Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    20. Russia Pegfilgrastim Biosimilars Market

    20.1. Russia Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    21. North America Pegfilgrastim Biosimilars Market

    21.1. North America Pegfilgrastim Biosimilars Market Overview

    21.2. North America Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    22. USA Pegfilgrastim Biosimilars Market

    22.1. USA Pegfilgrastim Biosimilars Market Overview

    22.2. USA Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    23. South America Pegfilgrastim Biosimilars Market

    23.1. South America Pegfilgrastim Biosimilars Market Overview

    23.2. South America Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    24. Brazil Pegfilgrastim Biosimilars Market

    24.1. Brazil Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    25. Middle East Pegfilgrastim Biosimilars Market

    25.1. Middle East Pegfilgrastim Biosimilars Market Overview

    25.2. Middle East Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    26. Africa Pegfilgrastim Biosimilars Market

    26.1. Africa Pegfilgrastim Biosimilars Market Overview

    26.2. Africa Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    27. Pegfilgrastim Biosimilars Market Competitive Landscape And Company Profiles

    27.1. Pegfilgrastim Biosimilars Market Competitive Landscape

    27.2. Pegfilgrastim Biosimilars Market Company Profiles

    27.2.1. Mylan

    27.2.1.1. Overview

    27.2.1.2. Products and Services

    27.2.1.3. Strategy

    27.2.1.4. Financial Performance

    27.2.2. Biocon

    27.2.2.1. Overview

    27.2.2.2. Products and Services

    27.2.2.3. Strategy

    27.2.2.4. Financial Performance

    27.2.3. Mundipharma

    27.2.3.1. Overview

    27.2.3.2. Products and Services

    27.2.3.3. Strategy

    27.2.3.4. Financial Performance

    27.2.4. Pfizer

    27.2.4.1. Overview

    27.2.4.2. Products and Services

    27.2.4.3. Strategy

    27.2.4.4. Financial Performance

    27.2.5. Sandoz

    27.2.5.1. Overview

    27.2.5.2. Products and Services

    27.2.5.3. Strategy

    27.2.5.4. Financial Performance

    28. Pegfilgrastim Biosimilars Pipeline Analysis

    29. Key Mergers And Acquisitions In The Pegfilgrastim Biosimilars Market

    30. Pegfilgrastim Biosimilars Market Future Outlook and Potential Analysis

    31. Appendix

    31.1. Abbreviations

    31.2. Currencies

    31.3. Historic And Forecast Inflation Rates

    31.4. Research Inquiries

    31.5. The Business Research Company

    31.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2017-2022, $ Billion
  • Table 2: Global Forecast Market Growth, 2022-2027F, 2032F, $ Billion
  • Table 3: Global Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 4: Global Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 5: Global Pegfilgrastim Biosimilars Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 6: Global Pegfilgrastim Biosimilars Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 7: Asia-Pacific, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 8: China, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 9: India, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 10: Japan, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 11: Australia, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 12: Indonesia, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 13: South Korea, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 14: Western Europe, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 15: UK, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 16: Germany, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 17: France, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 18: Eastern Europe, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 19: Russia, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 20: North America, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 21: USA, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 22: South America, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 23: Brazil, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 24: Middle East, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 25: Africa, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 26: Mylan Financial Performance
  • Table 27: Biocon Financial Performance
  • Table 28: Mundipharma Financial Performance
  • Table 29: Pfizer Financial Performance
  • Table 30: Sandoz Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2017-2022, $ Billion
  • Figure 2: Global Forecast Market Growth, 2022-2027F, 2032F, $ Billion
  • Figure 3: Global Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 4: Global Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 5: Global Pegfilgrastim Biosimilars Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 6: Global Pegfilgrastim Biosimilars Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 7: Asia-Pacific, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 8: China, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 9: India, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 10: Japan, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 11: Australia, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 12: Indonesia, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 13: South Korea, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 14: Western Europe, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 15: UK, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 16: Germany, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 17: France, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 18: Eastern Europe, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 19: Russia, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 20: North America, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 21: USA, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 22: South America, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 23: Brazil, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 24: Middle East, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 25: Africa, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 26: Mylan Financial Performance
  • Figure 27: Biocon Financial Performance
  • Figure 28: Mundipharma Financial Performance
  • Figure 29: Pfizer Financial Performance
  • Figure 30: Sandoz Financial Performance
View Report
View Report
View Report
View Report
View Report
View Report
View Report
View Report